

Hong Kong Public Offering – White Form eIPO Service Provider Application Form 香港公開發售 – 白表eIPO服務供應商申請表格
Please use this application form if you are a White Form eIPO Service Provider and are applying for Hong Kong Offer Shares on behalf of underlying applicants.
倘閣下為白表eIPO服務供應商並代表相關申請人申請認購香港發售股份，請使用本申請表格。

**OcuMension**
歐康維視
Ocumention Therapeutics
歐康維視生物
(Incorporated in the Cayman Islands with limited liability)
(於開曼群島註冊成立的有限公司)

GLOBAL OFFERING
全球發售

Number of Offer Shares under the Global Offering 全球發售的發售股份數目	: 105,930,000 Shares (subject to the Over-allotment Option) 105,930,000股股份(視乎超額配股權行使與否而定)
Number of Hong Kong Offer Shares 香港發售股份數目	: 10,593,000 Shares (subject to adjustment) 10,593,000股股份(可予調整)
Number of International Offering Shares 國際發售股份數目	: 95,337,000 Shares (subject to adjustment and the Over-allotment Option) 95,337,000股股份(可予調整及視乎超額配股權而定)
Maximum Offer Price 最高發售價	: HK\$14.66 per Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong Dollars and subject to refund) 每股股份14.66港元，另加1.0%經紀佣金、0.0027%證監會交易費及0.005%聯交所交易費(須於申請時以港元繳足及多繳股款可予退還)
Nominal value 面值	: US\$0.00001 per Share
Stock code 股份代號	: 1477

Please read carefully the prospectus of Ocumention Therapeutics (the “Company”) dated Monday, June 29, 2020 (the “Prospectus”) (in particular, the section on “How to Apply for Hong Kong Offer Shares” in the Prospectus) and the guide on the back of this Application Form before completing this Application Form. Terms defined in the Prospectus have the same meaning when used in this Application Form unless defined herein.

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange”), Hong Kong Securities Clearing Company Limited (“HKSCC”), the Securities and Futures Commission of Hong Kong (“SFC”) and the Registrar of Companies of Hong Kong take no responsibility for the contents of this Application Form, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of this Application Form.

A copy of this Application Form, together with a copy of each of the WHITE and YELLOW Application Forms, the Prospectus and the other documents specified in the section headed “Documents Delivered to the Registrar of Companies and Available for Inspection – Documents Delivered to the Registrar of Companies in Hong Kong” in Appendix V to the Prospectus have been registered by the Registrar of Companies in Hong Kong as required by Section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong). The SFC and the Registrar of Companies of Hong Kong take no responsibility as to the contents of any of these documents.

Your attention is drawn to the paragraph headed “Personal Data” in the section “How to Apply for Hong Kong Offer Shares” in the Prospectus which sets out the policies and practices of the Company and its Hong Kong Share Registrar in relation to personal data and compliance with the Personal Data (Privacy) Ordinance (Chapter 486 of the Laws of Hong Kong).

Nothing in this Application Form or the Prospectus constitutes an offer to sell or the solicitation of an offer to buy nor shall there be any sale of Hong Kong Offer Shares in any jurisdiction in which such offer, solicitation or sales would be unlawful. The information contained in this Application Form is not for distribution, directly or indirectly, in or into the United States (including its territories and dependencies, any State of the United States and the District of Columbia). These materials do not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The Shares mentioned herein have not been, and will not be, registered under the U.S. Securities Act and applicable U.S. state securities laws.

The Shares may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the U.S. Securities Act. No public offering of the securities will be made in the United States.

This Application Form and the Prospectus may not be forwarded or distributed or reproduced (in whole or in part) in any manner whatsoever in any jurisdiction where such forwarding, distribution or reproduction is not permitted under the law of that jurisdiction. This Application Form and the Prospectus are addressed to you personally. Any forwarding or distribution or reproduction of this Application Form or the Prospectus in whole or in part is unauthorised. Failure to comply with this directive may result in a violation of the U.S. Securities Act or the applicable laws of other jurisdictions.

The allocation of the Offer Shares between the Hong Kong Public Offering and the International Offering will be subject to adjustment as described in the section headed “Structure of the Global Offering – The Hong Kong Public Offering – Reallocation” in the Prospectus. In particular, the Joint Global Coordinators may reallocate Offer Shares from the International Offering to the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering. In accordance with Guidance Letter HKEx-GL19-18 issued by the Stock Exchange, if such reallocation is done other than pursuant to Practice Note 18 of the Listing Rules, the number of Offer Shares that may be reallocated from the International Offering to the Hong Kong Public Offering shall not exceed 10,593,000 Shares, representing approximately 10% of the Offer Shares initially available under the Global Offering, increasing the total number of Offer Shares available under the Hong Kong Public Offering to 21,186,000 Shares, representing approximately 20% of the Offer Shares and the final Offer Price shall be fixed at the bottom end of the indicative Offer Price range (i.e. HK\$13.16 per Offer Share) stated in the Prospectus.

If the number of Shares validly applied for in the Hong Kong Public Offering represents (i) 15 times or more but less than 50 times, (ii) 50 times or more but less than 100 times, and (iii) 100 times or more, of the number of Hong Kong Offer Shares available under the Hong Kong Public Offering, the total number of Hong Kong Offer Shares available under the Hong Kong Public Offering will be increased to 31,779,000 (in the case of (i)), 42,372,000 (in the case of (ii)), and 52,965,000 Shares (in the case of (iii)), respectively, representing approximately 30%, 40%, and 50% of the total number of Offer Shares initially available under the Global Offering, respectively (before any exercise of the Over-allotment Option). Further details of the reallocation are stated in the paragraph headed “Structure of the Global Offering – The Hong Kong Public Offering – Reallocation” of the Prospectus.

To: Ocumention Therapeutics
Joint Sponsors
Joint Global Coordinators
Joint Bookrunners
Hong Kong Underwriters

We confirm that we have (i) complied with the Guidelines for Electronic Public Offerings and the Operational Procedures for White Form eIPO applications submitted via Banks/Stockbrokers and all applicable laws and regulations (whether statutory or otherwise) in relation to the provision of our White Form eIPO services in connection with the Hong Kong Public Offering; and (ii) read the terms and conditions and application procedures set out in the Prospectus and this Application Form and agree to be bound by them. Applying on behalf of each of the underlying applicants to whom this application relates, we:

- apply for the number of Hong Kong Offer Shares set out below, on the terms and conditions of the Prospectus and this Application Form, and subject to the Articles of Association of the Company;
- enclose payment in full for the Hong Kong Offer Shares applied for, including 1% brokerage fee, 0.0027% SFC transaction levy and 0.005% Stock Exchange trading fee;
- confirm that the underlying applicants have undertaken and agreed to accept the Hong Kong Offer Shares applied for, or any lesser number allocated to such underlying applicants on this application;
- undertake and confirm that the underlying applicant(s) and the person for whose benefit the underlying applicant(s) is/are applying has/have not applied for or taken up, or indicated an interest for, or received or been placed or allocated (including conditionally and/or provisionally), and will not apply for or take up, or indicate an interest for, any Offer Shares under the International Offering nor otherwise participate in the International Offering;
- understand that these declarations and representations will be relied upon by the Company and the Joint Global Coordinators in deciding whether or not to make any allotment of Hong Kong Offer Shares in response to this application, and that the underlying applicants may be prosecuted if they made a false declaration;
- authorise the Company to place the name(s) of the underlying applicant(s) on the register of members of the Company as the holder(s) of any Hong Kong Offer Shares to be allotted to them, and the Company and/or its agents to send any Share certificate(s) (where applicable) by ordinary post at that underlying applicant’s own risk to the address specified in the application instruction of that underlying applicant in accordance with the procedures prescribed in this Application Form and in the Prospectus;
- request that any e-Refund payment instructions be despatched to the application payment account where the applicants had paid the application monies from a single bank account;
- request that any refund cheque(s) be made payable to the underlying applicant(s) who had used multiple bank accounts to pay the application monies and to send any such refund cheque(s) by ordinary post at that underlying applicant’s own risk to the address stated on the application in accordance with the procedures prescribed in this Application Form and in the Prospectus;
- confirm that each underlying applicant has read the terms and conditions and application procedures set out in this Application Form and in the Prospectus and in the designated website at www.eipo.com.hk, and agree to be bound by them;
- represent, warrant and undertake (a) that the underlying applicant(s) and any persons for whose benefit the underlying applicant(s) is/are applying is not restricted by any applicable laws of Hong Kong or elsewhere from making this application, paying any application monies for, or being allocated or taking up, any Hong Kong Offer Shares and the underlying applicant(s) and any persons for whose benefit the underlying applicant(s) is/are applying is/are outside the United States when completing and submitting the application and is/are a person described in paragraph (h)(3) of Rule 902 of Regulation S) and the underlying applicant(s) and any persons for whose benefit and the underlying applicant(s) is/are applying will acquire the Hong Kong Offer Shares in an offshore transaction (within the meaning of Regulation S); and (b) that the allocation of or application for the Hong Kong Offer Shares to the underlying applicant or by underlying applicant or for whose benefit this application is made would not require the Company, the Joint Sponsors, Joint Global Coordinators, Joint Bookrunners and the Hong Kong Underwriters or their respective officers or advisers to comply with any requirements under any law or regulation (whether or not having the force of law) of any territory outside Hong Kong; and
- agree that this application, any acceptance of it and the resulting contract, will be governed by and construed in accordance with the laws of Hong Kong.

在填寫本申請表格前，請細閱歐康維視生物(「本公司」)於2020年6月29日(星期一)刊發的招股章程(「招股章程」)(尤其是招股章程「如何申請香港發售股份」一節)及刊於本申請表格背面的指引。除非本申請表格另有定義，否則本申請表格所使用的詞語與招股章程所界定者具相同涵義。

香港交易及結算有限公司、香港聯合交易所有限公司(「聯交所」)、香港中央結算有限公司(「香港結算」)、香港證券及期貨事務監察委員會(「證監會」)及香港公司註冊處處長對本申請表格的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本申請表格全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。

本申請表格連同白色及黃色申請表格、招股章程及招股章程附錄五「送呈公司註冊處處長及備查文件—送呈香港公司註冊處處長文件」一節所列的其他文件，已遵照香港法例第32章公司(清盤及雜項條文)條例第342C條的規定，送呈香港公司註冊處處長登記。證監會及香港公司註冊處處長對任何此等文件的內容概不負責。

閣下敬請留意招股章程「如何申請香港發售股份」一節「個人資料」一段，當中載有本公司及其香港證券登記處有關個人資料及遵守香港法例第486章《個人資料(私隱)條例》的政策及措施。

本申請表格或招股章程所載者概不構成出售要約或要約購買的游說，而在任何作出有關要約、游說或出售即屬違法的司法管轄權區內，概不得出售任何香港發售股份。本申請表格所載資料，不得在或向美國(包括其領土及屬地、美國各州及哥倫比亞特區)境內直接或間接分發。該等資料不屬於或組成在美國購買或認購證券的任何要約或招攬的一部分。本申請表格所述股份並無且不會根據美國證券法及美國適用州證券法登記。

除非已進行登記或獲豁免遵守美國證券法的登記規定，否則不得於美國提呈發售或出售股份。證券不會在美國公開發售。

在任何根據有關司法管轄權區法律不得發送、派發或複製本申請表格及招股章程之司法管轄權區內，本申請表格及招股章程概不得以何方式發送或派發或複製(全部或部分)。本申請表格及招股章程僅致予閣下本人。概不得發送或派發或複製本申請表格或招股章程的全部或部分。如未能遵守此項指令，可能違反美國證券法或其他司法管轄權區的適用法律。

在香港公開發售與國際發售之間分配發售股份將受招股章程「全球發售的架構—香港公開發售—重新分配」一節所述調整規則。特別是，聯席全球協調人可將發售股份由國際發售重新分配至香港公開發售，以滿足根據香港公開發售作出的有效申請。根據聯交所發出的指引信HKEx-GL19-18，倘有關重新分配並非根據上市規則第18項應用指引作出，則可由國際發售重新分配至香港公開發售的發售股份數目不得超過10,593,000股，佔全球發售股份約20%，使香港公開發售項下可供認購的發售股份總數增至21,186,000股，佔發售股份約20%，及最終發售價須為招股章程所載的指示性發售價格範圍的下限(即每股發售股份13.16港元)。

倘香港公開發售有效申請的股份數目等於香港公開發售可供認購的香港發售股份數目的(i)15倍或以上但少於50倍；(ii)50倍或以上但少於100倍；及(iii)100倍或以上，則香港公開發售可供認購的香港發售股份總數將分別增至31,779,000股股份(如屬(i)的情況)、42,372,000股股份(如屬(ii)的情況)及52,965,000股股份(如屬(iii)的情況)，分別相當於全球發售初步可供認購發售股份總數的約30%、40%及50%(超額配股權獲任何行使前)。有關重新分配的進一步詳情請於招股章程「全球發售的架構—香港公開發售—重新分配」一段；

致：歐康維視生物
聯席保薦人
聯席全球協調人
聯席賬簿管理人
香港包銷商

吾等確認，吾等已(i)遵守《電子公開發售指引》及透過銀行/股票經紀遞交白表eIPO申請的運作程序以及與吾等就香港公開發售提供白表eIPO服務有關的所有適用法例及規則(不論法定或其他)；及(ii)閱讀招股章程及本申請表格所載條款及條件以及申請手續，並同意受其約束。為了代表與本申請有關的每名相關申請人作出申請，吾等：

- 按照招股章程及本申請表格的條款及條件，並在貴公司組織章程細則規限下，申請以下數目的香港發售股份；
- 夾附申請認購香港發售股份所需的全數款項(包括1%經紀佣金、0.0027%證監會交易費及0.005%聯交所交易費)；
- 確認相關申請人已承諾及同意接納所申請認購的香港發售股份，或該等相關申請人根據本申請獲分配的任何較少數目的香港發售股份；
- 承諾及確認相關申請人及相關申請人為其利益而提出申請的人士並無申請或承購或表示有意認購或收買或獲配售或分配(包括有條件及/或暫定)，並將不會申請或承購或表示有意認購國際發售的任何發售股份，亦不會以其他方式參與國際發售；
- 明白貴公司和聯席全球協調人將依賴此等聲明及陳述，以決定是否就本申請配發任何香港發售股份，及相關申請人如作出虛假聲明，可能會遭受檢控；
- 授權貴公司將相關申請人的姓名/名稱列入貴公司股東名冊內，作為任何將配發予相關申請人的香港發售股份的持有人，且貴公司及/或其代理可根據本申請表格及招股章程所載程序按相關申請人的申請指示所指定地址以普通郵遞方式寄發任何股票(如適用)，郵誤風險概由該相關申請人承擔；
- 倘申請人使用單一銀行賬戶支付申請股款，要求任何電子退款指示將發送至申請付款賬戶內；
- 要求任何退款支票以使用多個銀行賬戶支付申請股款的相關申請人為抬頭人，並根據本申請表格及招股章程所載程序將任何有關退款支票以普通郵遞方式寄發到申請所列的地址，郵誤風險概由該相關申請人承擔；
- 確認各相關申請人已閱讀本申請表格及招股章程以及指定網站www.eipo.com.hk所載條款及條件以及申請手續，並同意受其約束；
- 聲明、保證及承諾(a)相關申請人及相關申請人為其利益提出申請的人士並不受香港或其他地方之任何適用法律限制提出本申請，支付任何申請股款或獲配發或接納任何香港發售股份及相關申請人及相關申請人為其利益提出申請的人士在填寫及提交申請時身處美國境外及屬S規例第902條第(h)(3)段所述的人士且相關申請人及相關申請人為其利益提出申請的人士會於離岸交易(定義見S規例)中認購香港發售股份；及(b)向相關申請人或由相關申請人或為其利益而提出本申請的人士配發或申請認購香港發售股份，不會引致貴公司、聯席保薦人、聯席全球協調人、聯席賬簿管理人及香港包銷商或彼等各自的任何高級職員或顧問須遵從香港以外任何地區的法律或規則(不論是否具有法律效力)的任何規定；及
- 同意本申請、任何對本申請的接納以及因而訂立的合約，將受香港法律管轄及按其詮釋。

Signature 簽名	
Name of signatory 簽署人姓名	

Date 日期	
Capacity 身份	

We, on behalf of the underlying applicants, offer to purchase 吾等(代表相關申請人)要約購買	Total number of Shares 股份總數
---	--------------------------------

Hong Kong Offer Shares on behalf of the underlying applicants whose details are contained in the read only CD-ROM submitted with this application form.
代表相關申請人提出認購的香港發售股份(申請人的詳細資料載於連同本申請表格遞交的唯讀光碟)。

Total of 現夾附合共	cheques 支票	Cheque number(s) 支票號碼
are enclosed for a total sum of 總金額為	HK\$	
	港元	

4 Please use BLOCK letters 請用正體填寫

Name of White Form eIPO Service Provider 白表eIPO服務供應商名稱	White Form eIPO Service Provider ID 白表eIPO服務供應商身份證明號碼		
Chinese name 中文名稱	Contact number 聯絡電話號碼		
Name of contact person 聯絡人士姓名	Fax number 傳真號碼	For Broker use 此欄供經紀填寫 Lodged by 申請由以下經紀遞交	
Address 地址	Broker No. 經紀號碼		
	Broker's Chop 經紀印章		
	For bank use 此欄供銀行填寫		

GUIDE TO COMPLETING THIS APPLICATION FORM

References to boxes below are to the numbered boxes on this Application Form.

1 Sign and date the application form in Box 1. Only a written signature will be accepted.

The name and the representative capacity of the signatory should also be stated. To apply for Hong Kong Offer Shares using this Application Form, you must be named in the list of **White Form eIPO** Service Providers who may provide **White Form eIPO** services in relation to the Hong Kong Public Offering, which was released by the SFC.

2 Put in Box 2 (in figures) the total number of Hong Kong Offer Shares for which you wish to apply on behalf of the underlying applicants.

Applicant details of the underlying applicants on whose behalf you are applying must be contained in one data file in read-only CD-ROM format submitted together with this Application Form.

3 Complete your payment details in Box 3.

You must state in this box the number of cheque(s) you are enclosing together with this Application Form; and you must state on the reverse of each of those cheque(s) (i) your **White Form eIPO** Service Provider ID and (ii) the file number of the data file containing application details of the underlying applicant(s).

The dollar amount(s) stated in this box must be equal to the amount payable for the total number of Hong Kong Offer Shares applied for in Box 2.

All cheque(s) and this Application Form together with a sealed envelope containing the CD-ROM, if any, must be placed in the envelope bearing your company chop.

For payments by cheque, the cheque must:

- be in Hong Kong dollars;
- be drawn on a Hong Kong dollar bank account in Hong Kong;
- show your (or your nominee's) account name;
- be made payable to "BANK OF CHINA (HONG KONG) NOMINEES LIMITED – OCUMENSION THERAPEUTICS PUBLIC OFFER" (for **White Form eIPO**);
- be crossed "Account Payee Only";
- not be post dated; and
- be signed by the authorised signatories of the **White Form eIPO** Service Provider.

Your application may be rejected if any of these requirements is not met or if the cheque is dishonoured on its first presentation.

It is your responsibility to ensure that details on the cheque(s) submitted correspond with the application details contained in the CD-ROM or data file submitted in respect of this application.

The Company and the Joint Global Coordinators have full discretion to reject any applications in the case of discrepancies.

No receipt will be issued for sums paid on application.

4 Insert your details in Box 4 (using BLOCK letters).

You should write the name, ID and address of the **White Form eIPO** Service Provider in this box. You should also include the name and telephone number of the contact person at your place of business and where applicable, the Broker No. and Broker's Chop.

Personal Data

Personal Information Collection Statement

The main provisions of the Personal Data (Privacy) Ordinance (Chapter 486 of the Laws of Hong Kong) (the "Ordinance") came into effect in Hong Kong on December 20, 1996. This Personal Information Collection Statement informs the applicant for and holder of the Shares of the policies and practices of the Company and its Hong Kong Share Registrar in relation to personal data and the Ordinance.

1. Reasons for the collection of your personal data

From time to time it is necessary for applicants for securities or registered holders of securities to supply their latest correct personal data to the Company or its agents and/or its Hong Kong Share Registrar when applying for securities or transferring securities into or out of their names or in procuring the services of the Hong Kong Share Registrar.

Failure to supply the requested data may result in your application for securities being rejected or in delay or inability of the Company and/or the Hong Kong Share Registrar to effect transfers or otherwise render their services. It may also prevent or delay registration or transfer of the Hong Kong Offer Shares which you have successfully applied for and/or the despatch of Share certificate(s), and/or the despatch of e-Refund payment instructions, and/or the despatch of refund cheque(s) to which you are entitled.

It is important that holders of securities inform the Company and the Hong Kong Share Registrar immediately of any inaccuracies in the personal data supplied.

2. Purposes

The personal data of the applicants and the holders of securities may be used, held and/or stored (by whatever means) for the following purposes:

- processing of your application and e-Refund payment instructions/refund cheque, where applicable, and verification of compliance with the terms and application procedures set out in this form and the Prospectus and announcing results of allocation of the Hong Kong Offer Shares;
- enabling compliance with all applicable laws and regulations in Hong Kong and elsewhere;
- registering new issues or transfers into or out of the names of holders of securities including, where applicable, in the name of HKSCC Nominees;
- maintaining or updating the registers of holders of securities of the Company;
- conducting or assisting to conduct signature verifications, any other verification or exchange of information;
- establishing benefit entitlements of holders of securities of the Company, such as dividends, rights issues and bonus issues, etc;
- distributing communications from the Company and its subsidiaries;
- compiling statistical information and Shareholder profiles;
- making disclosures as required by laws, rules or regulations;
- disclosing identities of successful applicants by way of press announcement(s) or otherwise;
- disclosing relevant information to facilitate claims on entitlements; and
- any other incidental or associated purposes relating to the above and/or to enable the Company and the Hong Kong Share Registrar to discharge their obligations to holders of securities and/or regulators and/or any other purpose to which the holders of securities may from time to time agree.

3. Transfer of personal data

Personal data held by the Company and the Hong Kong Share Registrar relating to the holders of securities will be kept confidential but the Company and its Hong Kong Share Registrar may, to the extent necessary for achieving the above purposes or any of them, make such enquiries as they consider necessary to confirm the accuracy of the personal data and in particular, they may disclose, obtain, transfer (whether within or outside Hong Kong) the personal data of the holders of securities to, from or with any and all of the following persons and entities:

- the Company or its appointed agents such as financial advisers, receiving bankers and overseas principal share registrars;
- where applicants for securities request deposit into CCASS, to HKSCC and HKSCC Nominees, who will use the personal data for the purposes of operating CCASS;
- any agents, contractors or third-party service providers who offer administrative, telecommunications, computer, payment or other services to the Company and/or the Hong Kong Share Registrar in connection with the operation of their respective businesses;
- the Stock Exchange, the SFC and any other statutory, regulatory or governmental bodies; and
- any other persons or institutions with which the holders of securities have or propose to have dealings, such as their bankers, solicitors, accountants or stockbrokers, etc.

4. Retention of personal data

The Company and its Hong Kong Share Registrar will keep the personal data of the applicants and holders of securities for as long as necessary to fulfil the purposes for which the personal data were collected. Personal data which is no longer required will be destroyed or dealt with in accordance with the Ordinance.

5. Access and correction of personal data

The Ordinance provides the holders of securities with rights to ascertain whether the Company or the Hong Kong Share Registrar hold their personal data, to obtain a copy of that data, and to correct any data that is inaccurate. In accordance with the Ordinance, the Company and the Hong Kong Share Registrar have the right to charge a reasonable fee for the processing of any data access request. All requests for access to data or correction of data or for information regarding policies and practices and the kinds of data held should be addressed to the Company at its registered office disclosed in the "Corporate Information" section in the Prospectus or as notified from time to time in accordance with applicable law, for the attention of the Company secretary or (as the case may be) the Hong Kong Share Registrar for the attention of the Privacy Compliance Officer for the purposes of the Ordinance.

By signing this form, you agree to all of the above.

DELIVERY OF THIS APPLICATION FORM

This completed Application Form, together with the appropriate cheque(s) and a sealed envelope containing the CD-ROM, must be submitted to the following receiving bank by 4:00 p.m. on Friday, July 3, 2020:

Bank of China (Hong Kong) Limited
6/F, Bank of China Centre,
11 Hoi Fai Road,
West Kowloon

填寫本申請表格的指引

下文所述的號碼乃本申請表格中各欄的編號。

1 在申請表格欄1簽署及填上日期。僅接受親筆簽名。

簽署人的姓名及代表身份亦必須註明。如要使用本申請表格申請香港發售股份，閣下必須為名列於證監會公佈的白表eIPO服務供應商名單內可以就香港公開發售提供白表eIPO服務的人士。

2 在欄2填上閣下欲代表相關申請人申請認購的香港發售股份總數(請填寫數字)。

閣下代其作出申請的相關申請人資料，必須載於連同本申請表格遞交的一個唯讀光碟格式資料檔案內。

3 在欄3填上閣下付款的詳細資料。

閣下必須在此欄註明閣下連同本申請表格夾附的支票數目；並在每張支票的背面註明(i) 閣下的白表eIPO服務供應商身份證明號碼及(ii)載有相關申請人申請詳細資料的資料檔案的檔案編號。

此欄所註明的金額必須與欄2所申請認購的香港發售股份總數應付的金額相同。

所有支票及本申請表格，連同載有該唯讀光碟的密封信封(如有)必須放進蓋上閣下公司印章的信封內。

如以支票繳付股款，該支票必須：

- 為港元支票；
- 以在香港開設的港元銀行賬戶開出；
- 顯示閣下(或閣下代名人)的賬戶名稱；
- 註明抬頭人為「中國銀行(香港)代理人有限公司 – 歐康維視生物公開發售」(白表eIPO適用)；
- 以「只准入抬頭人賬戶」劃線方式開出；
- 不得為期票；及
- 由白表eIPO服務供應商的授權簽署人簽署。

倘未能符合任何此等規定或倘支票首次過戶不獲兌現，閣下的申請可遭拒絕受理。

閣下有責任確保所遞交的支票上的詳細資料與就本申請遞交的唯讀光碟或資料檔案所載的申請詳細資料相同。

倘出現差異，本公司及聯席全球協調人有絕對酌情權拒絕任何申請。

申請時繳付的款項將不會獲發收據。

4 在欄4填上閣下的詳細資料(用正楷填寫)。

閣下必須在此欄填上白表eIPO服務供應商的名稱、身份證明號碼及地址。閣下亦必須填寫閣下營業地點的聯絡人士的姓名及電話號碼及(如適用)經紀號碼及加蓋經紀印章。

個人資料

個人資料收集聲明

香港法例第486章《個人資料(私隱)條例》(「條例」)中的主要條文於1996年12月20日在香港生效。此項個人資料收集聲明是向股份申請人及持有人說明本公司及其香港證券登記處有關個人資料及條例方面的政策及措施。

1. 收集閣下個人資料的原因

證券申請人或證券登記處持有人申請證券或將證券轉往其名下，或將名下證券轉讓予他人，或要求香港證券登記處提供服務時，須不時向本公司或其代理及/或其香港證券登記處提供其最新的準確個人資料。

未能提供所要求的資料可能導致閣下的證券申請被拒絕或延遲，或本公司及/或香港證券登記處無法落實證券轉讓或提供服務。此舉亦可能妨礙或延遲登記或轉讓閣下獲接納申請的香港發售股份及/或寄發股票及/或發送電子退款指示及/或寄發閣下應得的退款支票。

證券持有人所提供的個人資料如有任何錯誤，須立即通知本公司及香港證券登記處。

2. 用途

證券申請人及持有人的個人資料可作以下用途使用、持有及/或保存(不論何種方式)：

- 處理閣下的申請及電子退款指示/退款支票(如適用)及核實是否符合本表格及招股章程所載條款及申請手續及公佈香港發售股份的分配結果；
- 以遵守香港及其他地區的所有適用法律及法規；
- 以證券持有人(包括以香港結算代理人(如適用))的名義登記新發行證券或轉讓或受讓證券；
- 存置或更新本公司證券持有人的名冊；
- 進行或協助進行簽名核對、任何其他核對或交換資料；
- 確定本公司證券持有人的受益權利，如股息、供股及紅股等；
- 分發本公司及其附屬公司的公司通訊；
- 編製統計資料及股東資料；
- 遵照法例、規則或規例的要求作出披露；
- 透過報章公告或其他方式披露獲接納申請人士的身份；
- 披露有關資料以便就權益提出申索；及
- 與上述者有關的任何其他附帶或相關用途及/或使本公司及香港證券登記處能履行對證券持有人及/或監管機構承擔的責任及/或證券持有人不時同意的任何其他用途。

3. 轉交個人資料

本公司及香港證券登記處會對證券持有人的個人資料保密，但本公司及其香港證券登記處可在將資料用作上述用途的必要情況下作出彼等認為必要之查詢以確定個人資料的準確性，尤其可能會向下列任何及所有人士及機構披露、獲取或轉交證券持有人的個人資料(無論在香港境內或境外)：

- 本公司或其委任的代理，如財務顧問、收款銀行及主要海外股份過戶登記處；
- (如證券申請人要求將證券存於中央結算系統)香港結算或香港結算代理人；彼等將會就中央結算系統的運作使用有關個人資料；
- 向本公司及/或香港證券登記處提供與其各自業務運作有關的行政、電訊、電腦、付款或其他服務的任何代理人、承包商或第三方服務供應商；
- 聯交所、證監會及任何其他法定、監管或政府機關；及
- 證券持有人與其進行或擬進行交易的任何其他人士或機構，如其銀行、律師、會計師或股票經紀等。

4. 個人資料的保留

本公司及其香港證券登記處將按收集個人資料所需的用途保留證券申請人及持有人的個人資料。無需保留的個人資料將會根據條例銷毀或處理。

5. 查閱及更正個人資料

條例賦予證券持有人權利以確定本公司或香港證券登記處是否持有其個人資料、索取有關資料副本及更正任何不準確之資料。根據條例規定，本公司及香港證券登記處有權就處理任何查閱資料的要求收取合理費用。所有關於查閱資料或更正資料或查詢有關政策及措施的資料及所持有資料類別的要求，應按照招股章程「公司資料」一節中披露的本公司註冊辦事處或根據適用法律不時通知的地址，向本公司的公司秘書或香港證券登記處屬下就條例所指的私隱事務主任(視乎情況而定)提出。

閣下簽署本表格，即表示同意上述所有規定。

遞交本申請表格

經填妥的本申請表格，連同相關支票及載有唯讀光碟的密封信封，必須於2020年7月3日(星期五)下午四時正前，送達下列收款銀行：

中國銀行(香港)有限公司
西九龍
海輝道11號
中銀中心6樓